Selective glycogen phosphorylase inhibitor [IC50
values are 0.017 and 0.034 μ
M against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle.
Baker et al.
Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-ca
Suh et al.
Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme.
Freeman et al.
The citations listed below are publications that use Tocris products. Selected citations for CP 316819 include:
Showing Results 1 - 1 of 1